The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat

International Journal of Neuropsychopharmacology

Volumn 16, Issue 2, 2013, Pages 417-432

  Steiner, Michel Alexander ^a   Lecourt, Hugues ^a   Jenck, François ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Addiction; almorexant; conditioned place preference; locomotor sensitization; orexin

Indexed keywords

ALMOREXANT; AMPHETAMINE; COCAINE; HYDROXYBUTYRIC ACID; MORPHINE;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; LOCOMOTION; MALE; NEUROPHARMACOLOGY; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; SENSITIZATION;

ACETAMIDES; AMPHETAMINE; ANESTHETICS; ANIMALS; COCAINE; CONDITIONING, OPERANT; DOPAMINE AGENTS; DRUG INTERACTIONS; FLAVOPROTEINS; ISOQUINOLINES; LOCOMOTION; MALE; MORPHINE; RATS; RATS, SPRAGUE-DAWLEY; REWARD;

EID: 84875054293     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000193     Document Type: Article

References (55)

1. Aston-Jones G, Smith RJ, Moorman DE, Richardson KA (2009). Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 56 (Suppl. 1), 112-121.
2. Balcita-Pedicino JJ, Sesack SR (2007). Orexin axons in the rat ventral tegmental area synapse infrequently onto dopamine and gamma-Aminobutyric acid neurons. Journal of Comparative Neurology 503, 668-684.
3. Baldo BA, Daniel RA, Berridge CW, Kelley AE (2003). Overlapping distributions of orexin/hypocretin-And dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress. Journal of Comparative Neurology 464, 220-237.
4. Bardo MT, Bevins RA (2000). Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berlin) 153, 31-43.
5. Barik J, Parnaudeau S, Saint Amaux AL, Guiard BP, et al. (2010). Glucocorticoid receptors in dopaminoceptive neurons, key for cocaine, are dispensable for molecular and behavioral morphine responses. Biological Psychiatry 68, 231-239.
6. Borgland SL, Chang SJ, Bowers MS, Thompson JL, et al. (2009). Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. Journal of Neuroscience 29, 11215-11225.
7. Borgland SL, Storm E, Bonci A (2008). Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. European Journal of Neuroscience 28, 1545-1556.
8. Borgland SL, Taha SA, Sarti F, Fields HL, et al. (2006). Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 49, 589-601.
9. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, et al. (2005). Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proceedings of the National Academy of Sciences USA 102, 19168-19173.
10. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, et al. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Medicine 13, 150-155.
11. Carter ME, Borg JS, de Lecea L (2009). The brain hypocretins and their receptors: mediators of allostatic arousal. Current Opinion in Pharmacology 9, 39-45.
12. Dietrich H, Jenck F (2010). Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology (Berlin) 212, 145-154.
13. Dugovic C, Shelton JE, Aluisio LE, Fraser IC, et al. (2009). Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. Journal of Pharmacology and Experimental Therapeutics 330, 142-151.
14. Fadel J, Deutch AY (2002). Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neuroscience 111, 379-387.
15. Fattore L, Martellotta MC, Cossu G, Fratta W (2000). Gamma-hydroxybutyric acid: an evaluation of its rewarding properties in rats and mice. Alcohol 20, 247-256.
16. Georgescu D, Zachariou V, Barrot M, Mieda M, et al. (2003). Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. Journal of Neuroscience 23, 3106-3111.
17. Gozzi A, Turrini G, Piccoli L, Massagrande M, et al. (2011). Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 6, e16406.
18. Griffiths RR, Johnson MW (2005). Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. Journal of Clinical Psychiatry 66 (Suppl. 9), 31-41.
19. Harris GC, Wimmer M, Aston-Jones G (2005). A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437, 556-559.
20. Hill ER, Tian J, Tilley MR, Zhu MX, et al. (2009). Potencies of cocaine methiodide on major cocaine targets in mice. PLoS One 4, e7578.
21. Hoever P, de Haas S, Winkler J, Schoemaker RC, et al. (2010). Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clinical Pharmacology and Therapeutics 87, 593-600.
22. Hollander JA, Lu Q, Cameron MD, Kamenecka TM, et al. (2008). Insular hypocretin transmission regulates nicotine reward. Proceedings of the National Academy of Sciences USA 105, 19480-19485.
23. Hutcheson DM, Quarta D, Halbout B, Rigal A, et al. (2011). Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward. Behavioral Pharmacology 22, 173-181.
24. Itzhak Y, Ali SF (2002). Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Annals of the New York Academy of Science 965, 451-460.
25. Jupp B, Krstew E, Dezsi G, Lawrence AJ (2011). Discrete cue-conditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin receptors. British Journal of Pharmacology 162, 880-889.
26. Kane JK, Parker SL, Matta SG, Fu Y, et al. (2000). Nicotine up-regulates expression of orexin and its receptors in rat brain. Endocrinology 141, 3623-3629.
27. Korotkova TM, Sergeeva OA, Eriksson KS, Haas HL, et al. (2003). Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. Journal of Neuroscience 23, 7-11.
28. Lawrence AJ, Cowen MS, Yang HJ, Chen F, et al. (2006). The orexin system regulates alcohol-seeking in rats. British Journal of Pharmacology 148, 752-759.
29. LeSage MG, Perry JL, Kotz CM, Shelley D, et al. (2010). Nicotine self-Administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology (Berlin) 209, 203-212.
30. Lettieri JT, Fung HL (1979). Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. Journal of Pharmacology and Experimental Therapeutics 208, 7-11.
31. Licata SC, Rowlett JK (2008). Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond. Pharmacology Biochemistry and Behavior 90, 74-89.
32. Narita M, Nagumo Y, Hashimoto S, Khotib J, et al. (2006). Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. Journal of Neuroscience 26, 398-405.
33. Narita M, Nagumo Y, Miyatake M, Ikegami D, et al. (2007). Implication of protein kinase C in the orexin-induced elevation of extracellular dopamine levels and its rewarding effect. European Journal of Neuroscience 25, 1537-1545.
34. O'Brien CP, Gardner EL (2005). Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacology and Therapeutics 108, 18-58.
35. Quarta D, Valerio E, Hutcheson DM, Hedou G, et al. (2010). The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization. Neurochemistry International 56, 11-15.
36. Robinson TE, Berridge KC (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews 18, 247-291.
37. Sakurai T, Mieda M, Tsujino N (2010). The orexin system: roles in sleep/wake regulation. Annals of the New York Academy of Sciences 1200, 149-161.
38. Saper CB, Cano G, Scammell TE (2005). Homeostatic, circadian, and emotional regulation of sleep. Journal of Comparative Neurology 493, 92-98.
39. Scammell TE, Winrow CJ (2011). Orexin receptors: pharmacology and therapeutic opportunities. Annual Review of Pharmacology and Toxicology 51, 243-266.
40. Sharf R, Guarnieri DJ, Taylor JR, DiLeone RJ (2010). Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. Brain Research 1317, 24-32.
41. Shoblock JR, Welty N, Aluisio L, Fraser I, et al. (2011). Selective blockade of the orexin-2 receptor attenuates ethanol self-Administration, place preference, and reinstatement. Psychopharmacology (Berlin) 215, 191-203.
42. Sinton CM (2011). Orexin/hypocretin plays a role in the response to physiological disequilibrium. Sleep Medicine Reviews 15, 197-207.
43. Smith RJ, See RE, Aston-Jones G (2009). Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. European Journal of Neuroscience 30, 493-503.
44. Smith RJ, Tahsili-Fahadan P, Aston-Jones G (2010). Orexin/hypocretin is necessary for context-driven cocaine-seeking. Neuropharmacology 58, 179-184.
45. Steiner MA, Lecourt H, Strasser DS, Brisbare-Roch C, et al. (2011). Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-Alpha1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology 36, 848-856.
46. Tsujino N, Sakurai T (2009). Orexin/Hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacology Reviews 61, 162-176.
47. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berlin) 151, 99-120.
48. Veeneman MM, Boleij H, Broekhoven MH, Snoeren EM, et al. (2011). Dissociable roles of mGlu5 and dopamine receptors in the rewarding and sensitizing properties of morphine and cocaine. Psychopharmacology (Berlin) 214, 863-876.
49. Watson J, Guzzetti S, Franchi C, Di Clemente A, et al. (2010). Gamma-hydroxybutyrate does not maintain self-Administration but induces conditioned place preference when injected in the ventral tegmental area. International Journal of Neuropsychopharmacology 13, 143-153.
50. Winrow CJ, Gotter AL, Cox CD, Doran SM, et al. (2011). Promotion of sleep by suvorexant-A novel dual orexin receptor antagonist. Journal of Neurogenetics 25, 52-61.
51. Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, et al. (2012). Pharmacological characterization of MK-6096-A dual orexin receptor antagonist for insomnia. Neuropharmacology 62, 978-987.
52. Winrow CJ, Tanis KQ, Reiss DR, Rigby AM, et al. (2010). Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 58, 185-194.
53. Zhang GC, Mao LM, Liu XY, Wang JQ (2007). Long-lasting up-regulation of orexin receptor type 2 protein levels in the rat nucleus accumbens after chronic cocaine administration. Journal of Neurochemistry 103, 400-407.
54. Zhou Y, Bendor J, Hofmann L, Randesi M, et al. (2006). Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. Journal of Endocrinology 191, 137-145.
55. Zhou Y, Cui CL, Schlussman SD, Choi JC, et al. (2008). Effects of cocaine place conditioning, chronic escalating-dose 'binge' pattern cocaine administration and acute withdrawal on orexin/hypocretin and preprodynorphin gene expressions in lateral hypothalamus of Fischer and Sprague-Dawley rats. Neuroscience 153, 1225-1234.